Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | ALDH1A1 | P00352 | 2/20 | 0.33 |
| ▸ | HSD17B10 | Q99714 | 2/20 | 0.33 |
| ▸ | MEN1 | O00255 | 2/20 | 0.33 |
| ▸ | LMNA | P02545 | 2/20 | 0.33 |
| ▸ | MAPT | P10636 | 2/20 | 0.33 |
| ▸ | KMT2A | Q03164 | 2/20 | 0.33 |
| ▸ | KDM4E | B2RXH2 | 1/20 | 0.33 |
| ▸ | BCHE | P06276 | 1/20 | 0.33 |
| ▸ | POLB | P06746 | 1/20 | 0.33 |
| ▸ | PTPRC | P08575 | 1/20 | 0.33 |
| ▸ | THRB | P10828 | 1/20 | 0.33 |
| ▸ | PKM | P14618 | 1/20 | 0.33 |
| ▸ | IDO1 | P14902 | 1/20 | 0.33 |
| ▸ | HPGD | P15428 | 1/20 | 0.33 |
| ▸ | ALOX15 | P16050 | 1/20 | 0.33 |
| ▸ | PTPN1 | P18031 | 1/20 | 0.33 |
| ▸ | ACHE | P22303 | 1/20 | 0.33 |
| ▸ | CES1 | P23141 | 1/20 | 0.33 |
| ▸ | RECQL | P46063 | 1/20 | 0.33 |
| ▸ | PTPN22 | Q9Y2R2 | 1/20 | 0.33 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL160698 | 1.00 | ALDH1A1 (0.33) | ALDH1A1HSD17B10MEN1LMNAMAPT | |
| SCHEMBL956606 | 0.83 | — | — | |
| SCHEMBL1245585 | 0.78 | KDM4E (0.35) | ALDH1A1HSD17B10MEN1LMNAMAPT | |
| SCHEMBL955074 | 0.72 | — | — | |
| SCHEMBL5056850 | 0.72 | — | — | |
| SCHEMBL5052532 | 0.69 | NPC1 (0.30) | HPGDTP53 | |
| SCHEMBL7593039 | 0.68 | SETD7 (0.33) | ALDH1A1HSD17B10MEN1LMNAMAPT | |
| SCHEMBL8655839 | 0.68 | — | — | |
| SCHEMBL8655845 | 0.68 | — | — | |
| SCHEMBL4500210 | 0.68 | — | — |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 80 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-12138261-B2 | Inhibitors of Bcl-2 | CASE WESTERN RESERVE UNIVERSITY (US) | 2024-11-12 | — | — | US | claimed |
| US-20220143135-A1 | INHIBITORS OF BCL-2 | UNIV CASE WESTERN RESERVE (US) | 2022-05-12 | — | — | US | claimed |
| US-11229641-B2 | Inhibitors of Bcl-2 | CASE WESTERN RESERVE UNIVERSITY (US) | 2022-01-25 | — | — | US | claimed |
| US-10058588-B2 | Inhibitors of BCL-2 | CASE WESTERN RESERVE UNIVERSITY (US) | 2018-08-28 | — | — | US | claimed |
| US-20180161391-A1 | INHIBITORS OF BCL-2 | UNIV CASE WESTERN RESERVE (US) | 2018-06-14 | — | — | US | claimed |
| US-20170224678-A1 | INHIBITORS OF BCL-2 | CASE WESTERN RESERVE UNIVERSITY | 2017-08-10 | — | — | US | claimed |
| EP-2242789-B1 | COPOLYMERS OF DIBENZODIAZOCINE WITH DIFUNCTIONAL MONOMERS CONTAINING SULFONE AND/OR KETONE UNITS | SOLVAY SPECIALTY POLYMERS USA (US) | 2017-05-24 | — | — | EP | claimed |
| CN-102803337-B | New polyamide, polyimide or polyamide-imide comprising dibenzodiazocine units | SOLVAY ADVANCED POLYMERS LLC | 2015-03-11 | — | — | CN | claimed |
| US-20130217633-A1 | INHIBITORS OF BCL-2 | CASE WESTERN RESERVE UNIVERSITY (US) | 2013-08-22 | — | — | US | claimed |
| US-8445441-B2 | Inhibitors of BCL-2 | CASE WESTERN RESERVE UNIVERSITY (US) | 2013-05-21 | — | — | US | claimed |
| WO-2011076674-A1 | NEW POLYAMIDE, POLYIMIDE OR POLYAMIDE-IMIDE COMPRISING DIBENZODIAZOCINE UNITS | SOLVAY ADVANCED POLYMERS, L.L.C. (US) | 2011-06-30 | — | — | WO | claimed |
| CN-101052666-B | Dibenzodiazocine polymers | SOLVAY ADVANCED POLYMERS LLC | 2011-06-29 | — | — | CN | claimed |
| US-20090048168-A1 | INHIBITORS OF BCL-2 | NATIONAL INSTITUTES OF HEALTH (NIH), U.S. DEPT. OF HEALTH AND HUMAN SERVICES (DHHS), U.S. GOVERNMENT | 2009-02-19 | — | — | US | claimed |
| EP-1740640-A4 | DIBENZODIAZOCINE POLYMERS | SOLVAY ADVANCED POLYMERS LLC (US) | 2008-06-04 | — | — | EP | claimed |
| JP-2007535591-A | — | — | 2007-12-06 | — | — | JP | claimed |
| CN-101052666-A | Dibenzodiazocine polymers | SOLVAY ADVANCED POLYMERS LLC (US) | 2007-10-10 | — | — | CN | claimed |
| US-7238771-B2 | Dibenzodiazocine polymers | SOLVAY ADVANCED POLYMERS, L.L.C. (US) | 2007-07-03 | — | — | US | claimed |
| EP-1740640-A2 | DIBENZODIAZOCINE POLYMERS | Solvay Advanced Polymers, L.L.C. (US) | 2007-01-10 | — | — | EP | claimed |
| US-20060058499-A1 | Dibenzodiazocine polymers | SOLVAY ADVANCED POLYMERS, L.L.C. | 2006-03-16 | — | — | US | claimed |
| WO-2005105922-A2 | DIBENZODIAZOCINE POLYMERS | SOLVAY ADVANCED POLYMERS, L.L.C. (US) | 2005-11-10 | — | — | WO | claimed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (8 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20170224678-A1 | INHIBITORS OF BCL-2 | BCL2, BAX, BAK1 | ALDH1A1 4242/4885HSD17B10 2919/4885MEN1 4271/4885 |
| US-20090048168-A1 | INHIBITORS OF BCL-2 | BCLAF1, BID, BCL2L1 | ALDH1A1 4729/4885HSD17B10 3735/4885MEN1 2843/4885 |
| US-20180161391-A1 | INHIBITORS OF BCL-2 | BCLAF1, BCL2L1, BCL2L11 | ALDH1A1 4636/4885HSD17B10 2415/4885MEN1 2500/4885 |
| US-20130217633-A1 | INHIBITORS OF BCL-2 | BCLAF1, BCL2L1, BCL2L11 | ALDH1A1 4636/4885HSD17B10 2415/4885MEN1 2500/4885 |
| US-11229641-B2 | Inhibitors of Bcl-2 | BCL2, BAX, BAK1 | ALDH1A1 4242/4885HSD17B10 2919/4885MEN1 4271/4885 |
| US-12138261-B2 | Inhibitors of Bcl-2 | BCL2, BAX, BAK1 | ALDH1A1 4242/4885HSD17B10 2919/4885MEN1 4271/4885 |
| US-20220143135-A1 | INHIBITORS OF BCL-2 | BCL2, BAX, BAK1 | ALDH1A1 4242/4885HSD17B10 2919/4885MEN1 4271/4885 |
| US-10058588-B2 | Inhibitors of BCL-2 | BCLAF1, BCL2L1, BCL2L11 | ALDH1A1 4636/4885HSD17B10 2415/4885MEN1 2500/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.